CL2017002065A1 - Proteasas de cisteína - Google Patents

Proteasas de cisteína

Info

Publication number
CL2017002065A1
CL2017002065A1 CL2017002065A CL2017002065A CL2017002065A1 CL 2017002065 A1 CL2017002065 A1 CL 2017002065A1 CL 2017002065 A CL2017002065 A CL 2017002065A CL 2017002065 A CL2017002065 A CL 2017002065A CL 2017002065 A1 CL2017002065 A1 CL 2017002065A1
Authority
CL
Chile
Prior art keywords
cysteine proteases
methods
polypeptide
vvo
lgg
Prior art date
Application number
CL2017002065A
Other languages
English (en)
Inventor
Christian Kjellman
Sofia Jarnum
Emma Nordahl
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of CL2017002065A1 publication Critical patent/CL2017002065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

<p>La presente invención se refiere a un polipéptido novedoso qua exhibe actividad de proteasa de cisteina de lgG y usos in vivo y ex vvo de Ins mismos. Usos del polipéptido incluyen métodos para la prevención o tratamiento de enfermedades y alecciones mediadas por IgG, y métodos para el análisis de 19G.</p>
CL2017002065A 2015-02-12 2017-08-11 Proteasas de cisteína CL2017002065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein

Publications (1)

Publication Number Publication Date
CL2017002065A1 true CL2017002065A1 (es) 2018-04-02

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002065A CL2017002065A1 (es) 2015-02-12 2017-08-11 Proteasas de cisteína

Country Status (23)

Country Link
US (4) US10696959B2 (es)
EP (2) EP4108768A1 (es)
JP (1) JP6961486B2 (es)
KR (1) KR102524613B1 (es)
CN (2) CN114231512A (es)
AU (2) AU2016217800B2 (es)
BR (1) BR112017017284A2 (es)
CA (1) CA2976003A1 (es)
CL (1) CL2017002065A1 (es)
CO (1) CO2017009061A2 (es)
DK (1) DK3256580T3 (es)
EA (1) EA035130B1 (es)
ES (1) ES2927234T3 (es)
GB (1) GB201502306D0 (es)
IL (1) IL253938B (es)
LT (1) LT3256580T (es)
MX (1) MX2017010390A (es)
MY (1) MY188696A (es)
PL (1) PL3256580T3 (es)
PT (1) PT3256580T (es)
SG (1) SG11201706346QA (es)
WO (1) WO2016128558A1 (es)
ZA (1) ZA201705113B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
BR112022006530A2 (pt) 2019-10-17 2022-07-05 Stridebio Inc Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
WO2021112925A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CA3164714A1 (en) 2020-02-14 2021-08-19 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
CN115066261A (zh) 2020-06-05 2022-09-16 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素ＩｄｅＥの突然変異体
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
CA3237815A1 (en) 2021-11-15 2023-05-19 Raghuveer RANGANATHAN Methods for enhancing adoptive cell transfer immunotherapies
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU2002216863B8 (en) 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
SI1601770T1 (sl) * 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CA2611646C (en) 2005-06-09 2015-08-11 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
US7544577B2 (en) 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
WO2009033670A2 (en) 2007-09-14 2009-03-19 Genovis Ab Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection
CA2708260A1 (en) 2007-12-13 2009-06-18 Intervacc Ab Improved immunizing composition
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
WO2010089126A2 (en) 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
AU2011258898B2 (en) 2010-05-26 2015-05-07 Intervacc Ab Vaccine against Streptococcal infections based on recombinant proteins
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Also Published As

Publication number Publication date
ZA201705113B (en) 2024-01-31
IL253938B (en) 2020-01-30
MY188696A (en) 2021-12-23
EP4108768A1 (en) 2022-12-28
EP3256580B1 (en) 2022-07-06
AU2016217800A1 (en) 2017-08-10
MX2017010390A (es) 2017-12-07
ES2927234T3 (es) 2022-11-03
CN114231512A (zh) 2022-03-25
US10696959B2 (en) 2020-06-30
KR102524613B1 (ko) 2023-04-21
US20200283749A1 (en) 2020-09-10
GB201502306D0 (en) 2015-04-01
US20230357741A1 (en) 2023-11-09
AU2021266293A1 (en) 2021-12-09
CO2017009061A2 (es) 2018-01-16
SG11201706346QA (en) 2017-09-28
US11214784B2 (en) 2022-01-04
CN107532156A (zh) 2018-01-02
EA035130B1 (ru) 2020-04-30
AU2016217800B2 (en) 2021-08-12
JP6961486B2 (ja) 2021-11-05
PL3256580T3 (pl) 2022-11-28
WO2016128558A1 (en) 2016-08-18
BR112017017284A2 (pt) 2018-04-17
JP2018506286A (ja) 2018-03-08
US11667905B2 (en) 2023-06-06
EP3256580A1 (en) 2017-12-20
PT3256580T (pt) 2022-10-03
EA201791773A1 (ru) 2018-02-28
KR20170116137A (ko) 2017-10-18
LT3256580T (lt) 2022-10-10
IL253938A0 (en) 2017-10-31
CA2976003A1 (en) 2016-08-18
US20180023070A1 (en) 2018-01-25
US20220170004A1 (en) 2022-06-02
DK3256580T3 (en) 2022-10-03

Similar Documents

Publication Publication Date Title
CL2017002065A1 (es) Proteasas de cisteína
ZA201705114B (en) Cysteine protease
JOP20200192A1 (ar) أجسام مضادة لـ tigit
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UY36701A (es) Tratamiento contra el cáncer por manipulación de la microflora comensal
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112016019274A2 (pt) agentes terapêuticos glico-orientados
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
DK3542635T3 (da) Valleproteinbaseret yoghurtlignende produkt med højt proteinindhold, ingrediens egnet til fremstilling deraf og fremgangsmåde til fremstilling.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
MX2017013601A (es) Un proceso de etapas multiples para la produccion de no.
BR112016007816A2 (pt) composições peptídicas inovadoras
DK3270950T3 (da) Isolerede peptider og fragmenter deraf fra fibrinogen til anvendelse som lægemidler, især ved inflammatoriske hudsygdomme
WO2016096640A3 (en) Anti-cxcl12 antibody molecules and their uses